At the 2025 AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases, held April 1-5 in Vienna, Austria, Quanterix presented over 80 posters, presentations, and sessions that featured our Simoa technology. Over the years, Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum, or plasma, with the ability to quantify proteins that are far lower than the level of quantification.

During the meeting, NeurologyLive® sat down with Mark Roskey, PhD, chief scientific officer at Quanterix, to discuss the company’s technology, its function, and role in the diagnosis of AD. In the discussion, Roskey highlighted the critical role of phosphorylated tau (p-tau)217 as the leading biomarker for early detection and disease monitoring, as well as advancements in multiplex biomarker panels that combine markers like glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and amyloid proteins for more comprehensive analysis. In addition, he spoke on the recently introduced Lucent AD Complete, a newly launched diagnostic tool designed to improve clarity in AD testing by reducing ambiguous results.